Immunosuppression is the major modifiable risk factor for development of PTDM but risk versus benefit analysis is required to balance risk of developing PTDM versus rejection.
Epidemiology and pathogenesis of postransplant diabetes mellitus
The clinical importance of post-transplant diabetes mellitus (PTDM) relies on its unquestionable impact as a significant risk factor for cardiovascular disease in solid organ transplantation [1, 2] . Cardiovascular disease is one of the leading causes of death with functioning graft and is associated with reduced kidney graft survival, infections and increased health-care costs.Based upon classical diagnostic approaches, a recent systematic review highlighted the incidence of PTDM to be a mean of 19.5% at one-year post-transplantation in studies from the last decade [3] . However heterogeneity was observed across different centers and organs [4] . There was some debate regarding the incremental incidence of PTDM beyond the first year post-transplantation and whether that differs between transplant versus the general population. Moreover it is unclear whether incidence of PTDM is increasing; Valderhaug et al. versus 20%) respectively [5] . However recent output from the United States Renal Data System (USRDS) has reported PTDM rates approaching 40% in the adult population by the third year after transplantation [6] . Modality of diagnosis differs between these two cohorts and it is imperative to obtain definitive population-based cohort analyses to determine the true incidence and prevalence of PTDM. It is important to correctly identify patients with PTDM, which refers to newly diagnosed diabetes mellitus with persistent hyperglycemia in the posttransplantation period (symptoms of diabetes plus random plasma glucose ≥200mg/dl(11.1mmol/L) or fasting plasma glucose (FPG)≥126mg/dl(7mmol/L); or FPG≥200mg/dl during an oral glucose tolerance test; or HbA1c≥6.5%) [7] . It is different for those patients with impaired fasting glucose (FPG 100-126mg/dl (5.6-6,9mmol/L) and/or impaired glucose tolerance (IFG) (FPG<7mmol/L and 2 hour plasma glucose after an oral glucose 7.8-11mmol/L) [8] . However, since few studies have used the American Diabetes Association or World Health Organization definitions for PTDM or IFG, and fewer have employed oral glucose tolerance testing, the incidence of glucose metabolism abnormalities in the renal transplant population is underestimated.
The term New-Onset Diabetes After Transplantation (NODAT) was coined to acknowledge the pathophysiological insult from the milieu of transplantation on glycemic metabolism. However recent consensus opinion was that the term is misleading, as diabetes may not be new but simply unrecognized [8] . It also inadequately describes allograft recipients who develop diabetes post-transplantation after an earlier transient hyperglycemic period that resolves. Consensus agreement was to adopt the term Post-Transplantation Diabetes Mellitus (PTDM) as it encompasses all diabetes-related episodes relevant after transplantation; new-onset, unrecognized, gestational etc. The term pre-diabetes should be utilized to identify recipients with early non-PTDM glycemic abnormalities post-transplantation.
The main underlying pathophysiological mechanism of PTDMis pancreatic β-cell dysfunction in the context of insulin resistance, but the relative importance of each of these important components of glycemic metabolism is under intense debate. Available studies support insulin resistance [9] versus beta cell dysfunction [10] as the primary pathophysiological defect. The latter study, comparing glycemic metabolic profiles in 1,064 kidney allograft recipients versus 1,357 non-transplant patients, provides compelling evidence for β-cell dysfunction as the primary defect in PTDM. This is an important issue to resolve, as increased understanding of underlying pathophysiological mechanism should facilitate targeted interventional trials. The inter-relationship between insulin secretion and sensitivity, termed the disposition index, may be of greater clinical importance. A recent consensus panel supports the notion that PTDM has to be considered a distinct pathophysiological and clinical entity from type 1 or 2 diabetes mellitus.
Risk factors for postransplantation diabetes mellitus
Relevant reviews have described PTDM risk factors [11] .Some proposed no modifiable factors are: age, ethnicity, family history of diabetes mellitus, cause of end-stage renal failure, gender, HLA-mismatch, genetic susceptibility, innate immunity, donor characteristics and education.
On the other hand, the suggested modifiable factors are: obesity, impaired triglycerides metabolism, previous stress diabetes, metabolic syndrome, high pretransplantation triglyceride level, cytomegalovirus infection, hepatitis C virus infection, rejection episodes, antihypertensive agents (β-blockers, thiazide diuretics), biochemical abnormalities (low magnesium, high uric acid), imapired glomerular filtration rate and immunosuppression (tacrolimus, ciclosporin, sirolimus, corticosteroids).The two most relevant findings in the recent years in this area have beem our understanding of genetic polymorphisms leading to pancreatic β-cell dysfunction [12, 13] and metabolic syndrome [2] , as important PTDM risk factors. The literature continues to be updated describing PTDM risk factors such as lower alcohol consumption [14] , hypomagnesemia [15] , decreased regulatory T-cells [16] , or high renal resistance index [17] .
Further research is required to be able to distinguish associations from genuine risk factors in the context of PTDM.
Immunosuppression is acknowledged as the major modifiable risk factor for development of PTDM but risk versus benefit analysis is required to balance risk of developing PTDM versus rejection [11] .
The potential diabetogenic effect of some immunossuppressant drugs are caused by renowned pathways described in numerous studies (Figure 1 ). These findings may be of relevance for tailoring specific immunosuppressive regimens to patients with particular needs [18] . However, a recent Consensus expert panel concluded that no specific recommendation may be done regarding specific immunosuppressive protocols to avoid PTDM, as the main focus should be placed in major outcomes such as patient and graft survival [8] . 
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Corticosteroids
The diabetogenic potential of corticosteroids is dose dependent. The originating factors of alteration of glucose metabolism are principally worsen insuline-resistance and also have deleterious effects on insulin secretion and β-cells [19] : -Potentiation of insulin resistance. The insulin signalling cascades in skeletal muscles is related to glucocorticoid which produces a reduced glucose uptake and reduced glycogen synthesis [20] [21] [22] -Less insulin secretion. The expression of GLUT 2 and glucokinase is reduced and imply a decrease of insulin secretion [20] . Also dexamethasone stimulates transcription of serum and glucocorticoid-inducible kinase 1, upregulating the activity of voltage-gated K + channels and leading to reduced Ca 2+ entry through voltage-gated Ca 2+ channels with resultant decreased insulin release [23] [24] [25] .
-β-cells apoptosis. Glucocorticoids induce oxidative stress and the release of mitochondrial cytochrome c and suppress pro-survival factors such as nuclear factor-κB, leading to apoptotic cell death [26] .
A number of randomised controlled trials compiled in several meta-analyses have been published in the last decade (Table 1 ). In the first meta-analysis analyzing this topic in kidney allograft recipients, steroid-sparing and withdrawal strategies showed limited benefits in reducing new-onset diabetes after transplantation requiring any treatment [27] . A second metaanalysis included more studies (n=16) with less strict criteria, showing a 36% reduction in risk of PTDM amongst all steroid avoidance or withdrawal studies. Meticulous analyses of existing evidence, however, conclude that the benefit is not very important. Steroid avoidance (or limited use for a maximal duration of 2 weeks) was apparently associated with less frequent diabetes requiring any treatment; however, this decrease was only evident with CsA (RR 0.54, 95% CI 0.30 to 0.98), whereas this difference was not significant analysing tacrolimus studies (RR 0.75, 95% CI 0.32 to 1.77) [27, 28] .In tacrolimus treated allograft recipients, it seems that the more diabetogenic effect of tacrolimus outweighted the potential benefit of avoiding steroids in the development of new diabetes. Although the reduction in incidence was very significant in one European Tacrolimus study with steroid avoidance [29] , the significance disappeared when joined with the US double-blind steroid avoidance study with tacrolimus, which did not show such effect [30] . It is possible that high tacrolimus levels were responsible for the absence of such beneficial effect in this last study [31] . In the US trial, the proportions of patients with PTDM requiring therapy were similar between groups, those requiring insulin were lower with steroid withdrawal (4/107, 3.7%) vs maintenance (10/86 ,11.6%, P = 0.049). Moreover, the change in HbA1c from baseline was significantly smaller at all time points (except at 48 months) in the PTDM early steroid-withdrawal group, showing better diabetic control despite less insulin use [30] . The degree of glycemic burden from chronic low-dose corticosteroid therapy is unclear and therefore steroid avoidance/withdrawal strategies require careful risk/benefit assessment in the context of long-term outcomes [31] .The impact of steroid avoidance/withdrawal in the current era is all the more uncertain given the tendency to lower CNI target levels and rapid weaning of corticosteroids. Other strategies that can be employed include split corticosteroid dosing to reduce glycemic variability and hyperglycemia [33] .
Steroid withdrawal after 3 to 6 months of kidney transplantation
A recent metaanalysis has assessed the very limited evidence available on steroid sparing strategies in patients with pancreas or kidney-pancreas transplantation [34] . At six months, no significant differences were found between the steroid avoidance and late referral groups HbA1c: mean difference 0.08% (95% CI -0.99 to 1.15). Thirteen cohort studies showed that steroid-sparing and withdrawal strategies have benefits in lowering HbA1c.
Finally, in the two analyses on the effect of steroid sparing strategies after liver transplantation in PTDM incidence, steroid free or steroid withdrawal at any time post-liver transplantation was associated with a decreased incidence of PTDM [35, 36] .
Calcineurin inhibitors
CNI cause a decrease in insulin secretion by a direct toxin effect on pancreatic β-cells [19] and other mechanisms:
-Decreased insulin secretion. CsA binds to cyclophilin D in the mitocondrial permeability transition pore, blocking its opening and interfering to stimulation of insulin secretion [37] .
-Direct toxic effect on the pancreatic β-cells. CNIs regulate the dephosphorylation of nuclear factor of activated T-cell protein and CREB (cAMP-responsive element-binding transcription factor) activity-2. The dephosphorylation of these proteins regulates several target genes which are critical in β-cell survival, replication, and function. Tacrolimus binds intracellularly to FK506-binding protein 1B before docking in the calcineurin binding site, thus inhibiting calcineurin and decreasing β-cell replication and survival [20, 38] .
Furthermore, CsA induces inhibition of calcineurin activated leucine zipper-bearing-kinase, leading to β-cell apoptosis [39] .
Our evidence-based search found five meta-analyses (three in kidney transplantation, one in liver and one in lung) and two additional RCTs in kidney transplantation ( Table 2 ). The DIRECT study confirmed the greater diabetogenic effect (composite endpoint of PTDM/impaired fasting glucose) comparing tacrolimus versus cyclosporine post kidney transplantation in a randomized controlled trial, with no difference in adverse events [41] .
PTDM or IFG occurred in 73/281 CsA patients (26%) and 96/286 tacrolimus patients (33.6%), a marginal difference with a p = 0.046. Insulin secretion was reduced in both treatment arms with a more pronounced reduction in the tacrolimus arm. Insulin sensitivity was also reduced in both arms without difference between groups. However this was a short 6-month trial. In another long-term RCT comparing tacrolimus and CsA, The incidence of PTDM was significantly higher in tacrolimus arms, and the 1-year difference persisted throughout followup. Between the tacrolimus arms (twice-daily vs extended release), no meaningful difference in the incidence of diabetes markers existed [42] . [43] . The liver and lung trials also showed a higher incidence of PTDM with tacrolimus than with CsA [43, 44] .
mTOR inhibitors
There are a number of possible mechanisms by which sirolimus may cause PTDM, including impaired insulin-mediated suppression of hepatic glucose production, insulin resistance from ectopic triglyceride deposition, or direct β-cell toxicity [45] [46] [47] .
-Insulin secretion. In vitro, sirolimus may facilitate the opening of ATP sensitive potassium channels thereby impairing the insulin secretion in addition to suppressing the glucosestimulated insulin secretion via direct inhibition of Krebs cycle and decrease of mitochondrial ATP production [49] . In vivo, there is conflicting data, it shows that mTORC1 activation via protein kinase B (PKB/Akt) led to a progressive improvement in glucose tolerance and hyperinsulinemia as a result of increased cell mass and proliferation [50] .
-Less growth and proliferation of β-cells. The direct inhibition of the mTOR complex 1 (mTOR C1) turns on a reduced regulatory effect on critical regulators of β-cell cycle and proliferation.
-Regulation of cellular response to nutrients. In a physiological situation, inhibition of mTOR may induce insulin resistance by inhibiting mTOR/S6K1 pathway. However, in obesity, there is persistent activation of S6K1 which inhibits insulin-receptor substrate and therefore, insulin resistance can be reversed by inhibiting mTOR/S6K1 pathway.
Results of published controlled studies and meta-analyses are very consistent: although mTOR inhibitors may be diabetogenic, the incidence of PTDM is not increased by its use (Table 3 ). The recent controlled trial comparing CsA-everolimus with CsA-mycophenolic acid showed similar PTDM in both groups [52] . To date, only one controlled trial, prematurely withdraw due to excessive rejection incidence in the CNI-free arm, showed higher incidences of PTDM using the combination of tacrolimus-sirolimus than using sirolimus without CNI [53] . Johnston and colleagues analyzed data from the USRDS and found the use of sirolimus, regardless of whether it was combined with a CNI or an anti-metabolite (mycophenolate mofetil or azathioprine), was independently associated with an increased risk of NODAT [46] . Selection bias may be in the basis of these differences, as adjusted models are unable to compensate the propensity of using sirolimus combination in patients at higher risk of rejection and PTDM. Clearly, more information derived from unbiased controlled trials is needed to confirm that the combination tacrolimus plus mTOR inhibitor is not more diabetogenic than tacrolimus and mycophenolate.
Other recent trials have confirmed the absence of a meaningful effect of CNI-free mTOR inhibitor use in PTDM. In the kidney Symphony trial, the tacrolimus arm was associated with the highest incidence of PTDM defined as the need of stable insulin (10.6% vs 7.8% in sirolimus arm, p=0.02) [18] .
In the only RCT assessing PTDM risk with the use of mTOR inhibitors after liver transplantation, tacrolimus-based regimen was associated with higher incidence of PTDM than sirolimus-MMF [54] .
Induction antibody agents
Data in relation to the impact of induction therapy is very limited and no firm conclusions can be drawn. In a recent meta-analysis (5 studies, 492 patients), alemtuzumab was found to be associated with a borderline lower risk of developing PTDM than IL2 receptor antagonists [55] .
This could be due to CNI-and steroid-sparing strategies employed with alemtuzumab use or a diabetogenic effect of IL2 receptor antagonists. A single-centre retrospective study of 264 renal transplant recipients, suggested that induction with basiliximab was associated with a significantly greater risk of developing PTDM compared to no induction (51.5% versus 36.9%, p=0.017) at 10-weeks post-transplantation [56] .
Recommendations and future directions
Immunosuppression is the major modifiable risk factor for development of PTDM but risk versus benefit analysis is required to balance risk of developing PTDM versus rejection.
Although the use of tacrolimus appears to be associated with more frequent PTDM, it is possible that its use improves hard outcomes such as acute rejection, and patient/graft survival.
Clearly, the development of rejection and PTDM concomitantly result in the worst outcomes.
Therefore, and in agreement with a recent Consensus document, no specific recommendation can be made to advocate a definitive immunosuppressant strategy for allograft recipients based upon PTDM risk alone [8] . Caution is advisable in immunosuppressant adjustments in the event that PTDM develops based on current evidence. Such changes must only be made after accounting for individualized patient-specific risk factors. Physicians should choose and use immunosuppression regimens shown to have the best outcome for patient and graft survival, irrespective of PTDM risk.
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